Physician profile
Nirav D Shah
NPI 1023083607
$28,373.20
in general payments reported to CMS, 2019-2025
34 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,156 · 2020: $11K · 2021: $5,882 · 2022: $2,758 · 2023: $451 · 2024: $1,059 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,703.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $9,124.34 | 2019-2025 | Farxiga |
| Amgen INC. | $8,581.39 | 2019-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $3,615.70 | 2019-2020 | |
| Boston Scientific Corporation | $2,471.74 | 2019-2025 | Latitude Communicator Power Supply, Watchman Flx, Avvigo Guidance System |
| Janssen Pharmaceuticals, INC | $782.86 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $418.18 | 2019-2025 | |
| Abiomed | $408.19 | 2019-2022 | |
| Shockwave Medical, INC | $370.05 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $365.41 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $317.51 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $273.09 | 2019-2025 | |
| Abbott Laboratories | $245.81 | 2019-2025 | Aveir, Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.36 | 2024-2025 | Jardiance |
| Medtronic, INC. | $201.61 | 2021-2023 | Abre |
| Amarin Pharma, INC. | $146.99 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $135.57 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $129.25 | 2022-2025 | Verquvo |
| Glaxosmithkline, LLC. | $86.71 | 2025 | Shingrix, Arexvy |
| Biotronik Nro, INC. | $84.71 | 2025 | Prospera |
| Philips North America LLC | $51.11 | 2022-2023 | |
| Baxter Healthcare | $46.17 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Bridgebio Pharma, INC. | $43.25 | 2025 | Attruby |
| Medicomp INC | $40.94 | 2025 | Telepatch Cardiac Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $39.39 | 2024 | |
| Cvrx, INC. | $36.51 | 2024 | Barostim Neo System |
| Siemens Medical Solutions USA, INC. | $27.33 | 2025 | Diagnostic Ultrasound System |
| Kiniksa Pharmaceuticals International, Plc | $22.76 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.89 | 2025 | Lifevest |
| Scpharmaceuticals INC. | $18.51 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $17.30 | 2023 | Livalo |
| Angiodynamics, INC. | $16.09 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $14.44 | 2025 | Rhythm Express |
| Actelion Pharmaceuticals US, INC. | $14.04 | 2024 | Opsumit |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.